17 / 43
177
Lu-DOTATATE PRRT Improves PFS
N
Event, n (%)
Median PFS (95% CI)
Unstratified
P
value
Unstratified HR (95% CI)
177
Lu-DOTATATE +
octreotide LAR 30 mg
117
30 (25.6%)
28.4 (28.4; NE) months
<0.0001
0.214 (0.139; 0.330
)
Octreotide LAR 60 mg
114
78 (68.4%)
8.5 (5.8; 11.0) months
CI, confidence interval; HR, hazard ratio; NE, not evaluable; PFS, progression-free survival.
Analysis cutoff date: June 30, 2016.
P
value obtained from the log-rank test. HR obtained from the Cox regression model.
17
177
Lu-DOTATATE +
octreotide LAR 30 mg
117
101
90
76
67
56
27
18
10
5
2
0
Octreotide LAR 60 mg
114
85
57
41
29
21
5
3
3
0
0
0
100
80
60
% of Subjects Progression Free
40
20
0
3
6
9
12
15
18
21
24
27
30
33
Months
0
Subjects at risk:
Strosberg et al. ENETS 2018